RxDoctor Payments Data

Ian Sudbury, PA

Physician Assistant · Herriman, UTNPI 1316620131

Payments from drug & device makers

$1,661in general payments, 2019–2025

Across 67 payments — averaging $24.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$644
  • Boston Scientific$210
  • AbbVie$201
  • Axsome Therapeutics, Inc.$68
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$60
  • Boehringer Ingelheim$59
  • plus $420 from 17 others

What the payments were for

  • Travel & lodging$29718%
  • Food & beverage$1,31979%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,661 in reported general payments places this provider in the 80th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$10,288
Medicare patients
79
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate13$19,027
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen277$11,191
Xtampza ErOxycodone Myristate19$9,281
Sumatriptan Succinate11$9,061
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen294$8,844
Fentanyl27$6,962
Buprenorphine18$6,216
Oxycodone Hcl219$4,328
Gabapentin165$2,409
Tramadol Hcl159$2,352
Buprenorphine Hcl38$2,232
Tizanidine Hcl208$1,775
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$1,489
Morphine Sulfate ErMorphine Sulfate61$1,410
Lidocaine17$1,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$48$19,02713 claims
Collegium Pharmaceutical, Inc.Xtampza Er$33$9,28119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Herriman

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →